Get the Stockscreener App
5.55
7.14%
0.37
Pavmed Inc stock is traded at $5.55, with a volume of 260.
It is up +7.14% in the last 24 hours and up +0.18% over the past month.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, EsoCheck, and the Veris Cancer Care Platform.
See More
Previous Close:
$5.18
Open:
$5.09
24h Volume:
260
Relative Volume:
0.01
Market Cap:
$40.70M
Revenue:
$85,000
Net Income/Loss:
$-22.16M
P/E Ratio:
-0.1473
EPS:
-37.672
Net Cash Flow:
$-6.29M
1W Performance:
+6.73%
1M Performance:
+0.18%
6M Performance:
-41.39%
1Y Performance:
-56.05%
1-Day Range:
$5.09
$5.09
1-Week Range:
$4.75
$5.55
52-Week Range:
$3.85
$28.44
Pavmed Inc Stock (PAVM) Company Profile
Name
Pavmed Inc
Sector
Industry
Phone
(212) 949-4319
Address
360 MADISON AVENUE, NEW YORK, NY
Compare PAVM vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PAVM
Pavmed Inc
|
5.09 | 40.78M | 85,000 | -22.16M | -6.29M | -37.67 |
ABT
Abbott Laboratories
|
115.73 | 198.01B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
330.00 | 130.41B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
92.61 | 120.48B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
49.87 | 75.37B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
89.91 | 53.19B | 6.30B | 1.07B | 1.09B | 1.8406 |
Pavmed Inc Stock (PAVM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-30-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-05-20 | Initiated | Ascendiant Capital Markets | Buy |
| Jun-28-18 | Initiated | Maxim Group | Buy |
Pavmed Inc Stock (PAVM) Latest News
PAVmed (PAVM) Results Check: Profit Per Share Falls Below Its Benchmark under the Current Snapshot; Stock Move: Shares Finish 1.57% Up at the ClosePost-Earnings Reaction - Vinanet
WVU PCH updates their signage and navigation - AOL.com
VA touts psilocybin trial for vets, but relief could take time - AOL.com
Verasonics Appoints New Senior Vice President, Research & Development - AOL.com
PAVmed (PAVM) Report Card: The Available Earnings Metric Delivers a Miss at the Close; Post-Earnings Trading: The Stock Loses 4.98% in the Current UpdateProfitability Analysis - Vinanet
Former President of DePuy Synthes U.S. Joins Peptilogics Board - AOL.com
PAVmed Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:PAVM) 2026-08-17 - Seeking Alpha
St. Joseph's Health Now Offers Pluvicto For Advanced Prostate Cancer - AOL.com
Maxim Group Maintains PAVmed(PAVM.US) With Buy Rating, Maintains Target Price $16 - Moomoo
PAVmed Q2 2026 slides: loss narrows as device programs advance By Investing.com - Investing.com Nigeria
PAVmed Q2 2026 slides: loss narrows as cash position weakens By Investing.com - Investing.com Nigeria
PAVmed reports Q2 progress with Veris, Lucid, a... - Pluang
PAVmed (PAVM) Q2 2026 Earnings Call Transcript - The Globe and Mail
PAVmed Inc (PAVM) (Q2 2026) Earnings Call Highlights: Narrowing - GuruFocus
Pavmed Stock Price Forecast. Should You Buy PAVM? - StockInvest.us
PAVM Q1 2026 Earnings: EPS of -$4.42 Misses Consensus by 519%; Shares Rally 9.7%ROA Comparison - Vinanet
PAVmed Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
PAVM Q2 FY2026 earnings call - finance.biggo.com
PAVM Looks 288.7% Overvalued on GF Value™ - GuruFocus
Is PAVmed Inc (PAVM) Overvalued After Q2 Earnings Miss? EPS at -$0.55, Revenue at $0.05M; GF Score: 32/100 - GuruFocus
Form 8K PAVmed Inc For: 14 August By Investing.com - Investing.com Nigeria
Earnings call transcript: PAVmed narrows Q2 2026 loss as shares slip - Investing.com Australia
PAVmed Q2 2026 slides: loss narrows as cash position weakens - Investing.com
PAVmed Q2 Results: Revenue jumps to $33k, cash rises to $3.8m - scanx.trade
PAVmed Q2 2026 slides: loss narrows as device programs advance - Investing.com
PAVM: Q2 saw operational progress, positive clinical results, and improved financial positioning - TradingView
PAVM: Net loss narrowed and operational progress advanced, with regulatory milestones on track - TradingView
PAVmed Q2 2026 Earnings Call: Complete Transcript - Benzinga
Q2 2026 PAVmed Inc Earnings Call Transcript - GuruFocus
PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results - PR Newswire
PAVmed Inc. (PAVM) investor discloses 8.8% stake and trust holdings - Stock Titan
PAVmed Inc reports results for the quarter ended June 30Earnings Summary - TradingView
PAVmed (PAVM) Releases Q2 2026 Earnings: Revenue Miss and Continued Losses - Quiver Quantitative
PAVmed Inc. 2026: Revenue $33K, EPS ($0.87) — 10-Q Summary - TradingView
PAVmed Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
PAVmed subsidiary Lucid Diagnostics posts 2Q revenue of USD 1.5 million - Bitget
Vesalio Announces FDA 510(k) Clearance of pVasc NET, a Next-Generation Peripheral Mechanical Thrombectomy Device with Integrated Distal Filter - AOL.com
Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results - PR Newswire
Lucid Diagnostics (NASDAQ: LUCD) grows revenue but warns on going concern, debt load - Stock Titan
PAVmed Inc expected to post a loss of 47 cents a shareEarnings Preview - TradingView
PAVmed Inc (NASDAQ: PAVM) Share Price, PAVM Stock News, PAVM Share Price & Updates - Kalkine
PAVM Q2'26 Earnings: revenue estimate is 48.00K USD - TradingView
Lucid Diagnostics Secures Commercial Coverage - Moomoo
Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard® Esophageal DNA Test - Morningstar
PAVmed unit Lucid Diagnostics wins Concert commercial coverage policy for EsoGuard test - Bitget
P&F Products & Features GmbH Announces Acquisition of AVVie GmbH - AOL.com
Lucid's EsoGuard Is the Only Esophageal Precancer Test Meeting Coverage Criteria - Stock Titan
Lucid Diagnostics to Participate in Upcoming Investor Conferences - Morningstar
Academic Orthopaedic Consortium Launches POST™, the First National Digital Platform Connecting MedTech, Pharma, and Academic Orthopaedic Departments - AOL.com
Lucid Diagnostics Sets Boston Fireside Chat and Virtual Meetings - Stock Titan
Weekly Recap: Q2 2026 earnings call and EsoGuard/EsoCheck sales - tradingview.com
Pavmed Inc Stock (PAVM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.32%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):